Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Fabbri

Showing results (401-410 of 438) with videos related to

Pageof 44
Sort By:
European Journal of Internal Medicine|August 13, 2025
A person-centred clinical approach to the multimorbid patient with COPDBartolome R Celli, Leonardo M Fabbri, Abebaw M Yohannes, et al.
Nature Communications|October 3, 2024
ITER full model in MCNP for radiation safety demonstrationR Juarez, M Belotti, A Kolsek, et al.
International Journal of Chronic Obstructive Pulmonary Disease|February 25, 2022
Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle FluticasoneDavid B Price, William Henley, José Eduardo Delfini Cançado, et al.
Respiratory Research|January 8, 2017
A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary diseaseColin Reisner, Leonardo M Fabbri, Edward M Kerwin, et al.
American Journal of Respiratory and Critical Care Medicine|May 16, 2018
Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized TrialsFernando J Martinez, Klaus F Rabe, Peter M A Calverley, et al.
The European Respiratory Journal|December 14, 2022
Development of a tool to detect small airways dysfunction in asthma clinical practiceJanwillem Kocks, Thys van der Molen, Jaco Voorham, et al.
The Lancet. Respiratory Medicine|December 8, 2014
Regular versus as-needed budesonide and formoterol combination treatment for moderate asthma: a non-inferiority, randomised, double-blind clinical trialAlberto Papi, Brunilda Marku, Nicola Scichilone, et al.
Pragmatic and Observational Research|January 26, 2024
Risk of Pneumonia in Patients with COPD Initiating Fixed Dose Inhaled Corticosteroid (ICS) / Long-Acting Bronchodilator (LABD) Formulations Containing Extrafine Beclometasone Dipropionate versus Patients Initiating LABD Without ICSDavid Price, William Henley, José Eduardo Delfini Cançado, et al.
Forensic Science International. Genetics|August 25, 2012
The 2011 GeFI collaborative exercise. Concordance study, proficiency testing and Italian population data on the new ENFSI/EDNAP loci D1S1656, D2S441, D10S1248, D12S391, D22S1045C Previderè, P Grignani, F Alessandrini, et al.
Chest|December 6, 2016
Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPDFernando J Martinez, Klaus F Rabe, Gary T Ferguson, et al.
Pageof 44

Showing results (401-410 of 438) with videos related to

Sort By:
Pageof 44
European Journal of Internal Medicine|August 13, 2025
A person-centred clinical approach to the multimorbid patient with COPDBartolome R Celli, Leonardo M Fabbri, Abebaw M Yohannes, et al.
Nature Communications|October 3, 2024
ITER full model in MCNP for radiation safety demonstrationR Juarez, M Belotti, A Kolsek, et al.
International Journal of Chronic Obstructive Pulmonary Disease|February 25, 2022
Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle FluticasoneDavid B Price, William Henley, José Eduardo Delfini Cançado, et al.
Respiratory Research|January 8, 2017
A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary diseaseColin Reisner, Leonardo M Fabbri, Edward M Kerwin, et al.
American Journal of Respiratory and Critical Care Medicine|May 16, 2018
Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized TrialsFernando J Martinez, Klaus F Rabe, Peter M A Calverley, et al.
The European Respiratory Journal|December 14, 2022
Development of a tool to detect small airways dysfunction in asthma clinical practiceJanwillem Kocks, Thys van der Molen, Jaco Voorham, et al.
The Lancet. Respiratory Medicine|December 8, 2014
Regular versus as-needed budesonide and formoterol combination treatment for moderate asthma: a non-inferiority, randomised, double-blind clinical trialAlberto Papi, Brunilda Marku, Nicola Scichilone, et al.
Pragmatic and Observational Research|January 26, 2024
Risk of Pneumonia in Patients with COPD Initiating Fixed Dose Inhaled Corticosteroid (ICS) / Long-Acting Bronchodilator (LABD) Formulations Containing Extrafine Beclometasone Dipropionate versus Patients Initiating LABD Without ICSDavid Price, William Henley, José Eduardo Delfini Cançado, et al.
Forensic Science International. Genetics|August 25, 2012
The 2011 GeFI collaborative exercise. Concordance study, proficiency testing and Italian population data on the new ENFSI/EDNAP loci D1S1656, D2S441, D10S1248, D12S391, D22S1045C Previderè, P Grignani, F Alessandrini, et al.
Chest|December 6, 2016
Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPDFernando J Martinez, Klaus F Rabe, Gary T Ferguson, et al.
Pageof 44